B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRIN2B

MOLECULAR TARGET

glutamate ionotropic receptor NMDA type subunit 2B

UniProt: Q13224NCBI Gene: 290417 compounds

GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRIN2B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Glutamic Acid3.2224
2Glutamic Acid3.2224
3Glycine2.4010
4eliprodil2.4010
5pentamidine1.795
6Dextromethorphan Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of1.614
7Levorphanol1.614
8Aspartic Acid1.393
9cycloserine1.393
10D-Aspartic Acid1.102
11Dextrorphan Dextro form of levorphanol. It acts as1.102
12Ethidium1.102
13Dextrothyroxine0.691
14Dizocilpine Maleate0.691
15Ibotenic Acid0.691
16Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as0.691
17Spermine0.691

About GRIN2B as a Drug Target

GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented GRIN2B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRIN2B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.